Bloomage BioTechnology Corporation Limited
Bloomage BioTechnology Corporation Limited is a injectable hyaluronan soft tisse filling gel.
Launch date
Employees
Market cap
$4.0b
Enterprise valuation
$3.9b (Public information from Sep 2024)
Share price
CNY67.63 688363.SS
China (HQ)
Financials
Estimates*
CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 2.6b | 4.9b | 6.4b | 6.1b | 6.1b | 7.3b | 8.4b |
% growth | 40 % | 88 % | 29 % | (4 %) | 1 % | 19 % | 15 % |
EBITDA | 866m | 1.1b | 1.4b | 1.0b | 1.1b | 1.4b | 1.6b |
% EBITDA margin | 33 % | 22 % | 22 % | 17 % | 18 % | 19 % | 19 % |
Profit | 646m | 782m | 971m | 593m | 708m | 932m | 1.1b |
% profit margin | 25 % | 16 % | 15 % | 10 % | 12 % | 13 % | 13 % |
EV / revenue | 26.7x | 14.8x | 10.0x | 5.1x | 5.3x | 4.5x | 3.8x |
EV / EBITDA | 81.1x | 67.2x | 45.6x | 30.2x | 29.9x | 23.7x | 19.7x |
R&D budget | 141m | 284m | 388m | 446m | - | - | - |
R&D % of revenue | 5 % | 6 % | 6 % | 7 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
$85.0m | Post IPO Equity | ||
Total Funding | - |